Although results in mouse models indicated that learning and cognition would be the optimal primary targets for mGluR5 NAMs in FXS, and learning is the core problem in FXS, the regulatory environment and lack of good cognitive measures for FXS precluded a focus on learning in the initial human trials. This evidence concerns the gene GRM5 and fragile X syndrome.